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ABSTRACT 
Aims: The nuclear proliferation marker Ki67 assayed by immunohistochemistry has multiple 
potential uses in breast cancer, but an unacceptable level of inter-laboratory variability has 
hampered its clinical utility.  The International Ki67 in Breast Cancer Working Group has 
undertaken a systematic program to determine whether Ki67 measurement can be analytically 
validated and standardized across laboratories.  This study addresses whether acceptable 
scoring reproducibility can be achieved on excision whole sections. 
Methods and results: Adjacent sections from 30 primary ER+ breast cancers were centrally 
stained for Ki67 and sections were circulated among 23 pathologists in 12 countries. All 
pathologists scored Ki67 by two methods: (a) global: 4 fields of 100 tumor cells each were 
selected to reflect observed heterogeneity in nuclear staining; (b) hot-spot: the field with 
highest apparent Ki67 index was selected and up to 500 cells scored.  The intraclass correlation 
coefficient (ICC) for the global method (0.87; 95%CI: 0.799-0.93) marginally met the 
prespecified success criterion (lower 95%CI ≥ 0.8) while the ICC for the hot-spot method (0.83; 
95%CI: 0.74-0.90) did not.  Visually, inter-observer concordance in location of selected hot-spots 
varies between cases.  The median times for scoring were 9 and 6 minutes for global and hot-
spot methods, respectively. 
Conclusions: The global scoring method demonstrates adequate reproducibility to warrant next 
steps toward evaluation for technical and clinical validity in appropriate cohorts of cases.  The 
time taken for scoring by either method is practical using counting software we are making 
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publicly available.  Establishment of external quality assessment schemes is likely to improve 
the reproducibility between laboratories further.   
 
Keywords: Ki67, immunohistochemistry, pathology, scoring protocol, analytical validity, inter-
observer variability, inter-observer reproducibility   
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INTRODUCTION 
The nuclear antigen recognized by the Ki67 antibody is expressed in proliferating cells but 
absent in resting cells1.  Since its discovery in 1983 by Gerdes et al.,1 Ki67 assessed by 
immunostaining has been studied extensively as a prognostic2-11 and predictive4,6,9,12,13 marker, 
predominantly in hormone-receptor positive breast cancer but also in other tumors as well14-18.  
For example, pre-surgical Ki67 has been shown to be a marker for recurrence free survival19 and 
in the neoadjuvant setting, a marker for endocrine resistant tumor that may require more 
aggressive treatment20.  Excellent intra-observer reproducibility under controlled pre-analytic 
and staining conditions21 has contributed to the body of evidence showing the potential of Ki67 
immunohistochemistry assay to be implemented in hospital laboratories as a cost effective part 
of clinical management22-24.  However, poor inter-observer reproducibility and variability due to 
technical aspects of the assay has limited its adoption in clinical practice4,9,25-28. 
The International Ki67 Working Group (IKWG) has undertaken a systematic multiphase program 
to determine whether Ki67 scoring can be standardized and analytically validated across 
laboratories9,21,29,30.  In phase 1, as assessed by the intraclass correlation coefficient (ICC) 
estimate of inter-observer reproducibility, differences in pathologists’ visual interpretation 
were the main source of variability (ICC = 0.71, 95% credible interval (CI): 0.47–0.78)21.  In phase 
2, greater concordance was achieved, at least on tissue microarrays, when pathologists trained 
to calibrate and standardize scoring according to a clearly defined methodology (ICC = 0.94, 
95% CI: 0.90–0.97)29.  However, in clinical practice, decisions are made on core-cut biopsy or on 
excision specimens which require general assessment of the entire sample and selection of 
areas for formal counting.  Therefore, in phase 3A, we assessed whether acceptable 
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performance could be achieved on core-cut biopsies using a standardized method with two 
distinct methods of scoring field selection: global (four representative fields, counting 100 
nuclei each) and hot-spot (one field with highest Ki67, counting 500 nuclei).  The global method 
achieved acceptable inter-observer reproducibility (ICC = 0.87; 95% CI: 0.81–0.93) according to 
our prespecified criteria, whereas the hot-spot method did not (ICC = 0.84; CI: 0.77–0.92)30. 
This current study represents the final phase (3B) of the visual scoring analytical validity 
program, wherein we assess whether acceptable performance can be achieved on centrally 
stained excision whole sections using the scoring method established on core-cut biopsies.  
Future studies would be required to evaluate variability due to staining and pre-analytical 
aspects of the assay.   
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MATERIALS AND METHODS 
This study was approved by the British Columbia Cancer Agency Clinical Research Ethics Board 
(H10-03420).  All specimens used in this study were donated by patients who signed 
institutionally-appropriate consent forms, were excess to diagnostic requirements and ethically 
available for quality control studies.   
Case selection and sample preparation 
Excision blocks from 30 estrogen receptor (ER) positive breast cancer cases were selected: 15 
from the phase 3A study30 and 15 from Kawasaki Medical School Hospital, Kurashiki, Japan 
(Supplemental Figure 1).  Case selection was irrespective to patients’ age at diagnosis, tumor 
grade, size or nodal status.  The clinicopathological characteristics of these 30 cases are shown 
in Supplemental Table 1.  All blocks were sectioned and stained in the Royal Marsden Hospital 
Histopathology Department using monoclonal antibody MIB1 at dilution 1:50 (DAKO UK,  
Cambridgeshire, UK) using an automated staining system (Ventana Medical Systems, Tucson, 
Arizona, USA) according to criteria established by the IKWG9.  Sections from the same block 
were stained in a single immunohistochemistry run except for four cases where the staining 
was done in two different runs.  This approach effectively controls for any technical variation in 
staining.  
Sample distribution 
Twenty-four volunteer pathologists representing 24 institutions from 12 countries, most of 
whom participated in the phase 3A study, were invited to participate. 
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Six adjacent sections from each of the 30 excision blocks were centrally stained: the first with 
H&E, the second with p63 (myoepithelial marker, to assist the identification of invasive foci) 
and the third to sixth with Ki67 (designated as slide sets 1–4).  To facilitate application to the 
general histopathology laboratory environment, physical glass slides (as opposed to virtual slide 
images) were distributed to the volunteer pathologists.  Because the accumulated delays 
required, if all pathologists reviewed the same physical glass slides, would have made the study 
impractical, participating pathologists were divided into four groups and were given one of the 
four sets of Ki67 slides to score. The H&E and p63 reference slides were made available online 
as digital images.  Twenty-three pathologists successfully completed the study. 
Scoring protocol 
All pathologists were specifically trained to score Ki67 with emphasis on having a very low 
threshold for appreciating “brown stain” and the principles of standardized regions for nuclei 
counting, through the publicly available proficiency training module 
(http://www.gpec.ubc.ca/calibrator) that was initially used in the phase 2 study29.  The detailed 
scoring protocol is found in supplemental document: “ki67p3b_scoring_protocol.pdf”.  A 
modified version of the scoring software used in this study is available freely from the Google 
Play and Apple iTunes store (search term: “Ki67”). 
Scoring methods 
The scoring methods used are the same ones that were employed in the phase 3A study30: 1) a 
global assessment that is weighted according to the estimated percentage of the total cancer 
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area covered by each of high, medium, low, or negligible Ki67 staining levels; 2) an unweighted 
global assessment; and 3) assessment of Ki67 only in a “hot-spot” area.  
Global methods attempt to derive an average score across all the tissue available for 
assessment.  In the weighted and unweighted global methods, Ki67 index counting was 
performed in the same fashion, but the final Ki67 score was derived differently.  Adapted from 
a scoring protocol that has been used routinely in the Dowsett laboratory31,  these two global 
methods require the pathologist to first assess staining heterogeneity by estimating the 
percentages of the invasive tumor component of the slide exhibiting relatively high, medium, 
low or negligible Ki67 staining frequencies.  Based on these estimates, an algorithm 
(Supplemental Figure 2) dictates the required number of fields to select and score for each Ki67 
staining frequency (irrespective of staining intensity; totaling up to four fields).  This algorithm 
was designed such that the four (or less) selected scoring fields would capture the full range of 
staining frequencies while at the same time, be reflective of the proportion in staining 
frequencies heterogeneity.  Up to 100 invasive tumor nuclei within each field are counted using 
a “typewriter” pattern (Supplemental Figure 3), similar to how a tissue microarray core was 
scored in the phase 2 study29.   
The hot-spot method requires the pathologist to visually select one high-power field with the 
highest apparent staining rate and, within that area only, count up to 500 invasive tumor nuclei 
in a “typewriter” pattern. 
Statistical analyses 
Pre-specified criterion for success 
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Prior to data collection it was hypothesized that at least one of the scoring methods would have 
an associated ICC statistically greater than 0.80 (ICC of 0.8 being considered as good 
concordance32).  For planning purposes, power calculations performed under a variety of 
scenarios considered to represent good reproducibility (and similar to the results observed in 
the phase 2 study) showed that with at least 21 participating pathologists scoring 30 cases, 
there would be 80% power to exclude ICCs lower than the pre-specified ICC of 0.8 from a 95% 
credible interval for a given scoring method. 
Ki67 score 
The Ki67 score was defined as in the phase 3A study30.  Positive staining was defined as any 
brown stain in the nucleus above background, with reference available as needed to provide 
standard sample images; negative staining was scored when an invasive cancer cell showed 
only a blue counterstained nucleus.  The unweighted global and hot-spot scores were simply 
the total number of positively stained tumor nuclei counted divided by the total number of 
tumor nuclei counted.  The weighted global score was derived with tumor nuclei counts in each 
assessed field weighted by the estimated percentage of the total cancer area covered by each 
of high, medium, low, or negligible Ki67 staining levels.  As in our previous studies, to satisfy 
model assumptions of normality and constant variance, for statistical analyses the Ki67 score is 
converted to a logarithmic scale by adding 0.1% and applying a log base 2 transformation.  
ICC estimates (ranging from 0 to 1, with 1 representing perfect reproducibility) were computed 
as previously reported in the phase 3A study30.  Briefly, variance component analyses were 
performed to quantify the contributions from the following sources of variability: scoring 
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pathologist (observer), patient tumor (biological variation – each excision block represents a 
unique patient) and section of the excision block.  Similar to the phase 3A study, same-section 
and different-section ICCs were computed.  Same-section refers to pathologists scoring the 
same excision whole section physical slides, while different-section refers to pathologists 
scoring different physical slides that represent serial sections cut from the same original 
excision blocks.  Credible intervals for the variance components and the ICCs were obtained 
using the Markov Chain Monte Carlo routines for fitting generalized linear mixed models. 
All data analyses were performed using R version 3.3.233.  Sources of variation in log2-
transformed Ki67 scores were analyzed using random effects models as implemented in the R 
packages lme4 and MCMCglmm.  Data were visualized using heat maps, boxplots and spaghetti 
plots.  
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RESULTS 
ICC of Ki67 according to scoring method.  
The different-section ICC estimate for the weighted global scores was 0.87 (95%CI: 0.799─0.93), 
at the margin of the pre-specified success criterion (lower bound of credible interval exceeding 
0.8) (Table 1).  The different-section ICCs for the unweighted global scores and hot-spot scores 
were 0.86 (95%CI: 0.793─0.92) and 0.83 (95 %CI: 0.74─0.90), respectively, and therefore both 
these methods had ICC credible intervals that extended below the success criterion at the lower 
95% limit.  The corresponding same-section ICC estimates for the weighted global, unweighted 
global and hot-spot scores were virtually identical 0.87 (95% CI: 0.799─0.92), 0.86 (95% CI: 
0.79─0.92) and 0.83 (95% CI: 0.74─0.90) respectively, supporting that differences between 
serial sections were minimal.  Figure 1 displays the side-by-side boxplots of Ki67 scores across 
pathologists (hereafter referred to as “observers”) by group.  Summary statistics for the Ki67 
scores across the 23 observers are given in Supplemental Tables 2 to 4. 
The median number of nuclei counted per slide (across all observers and cases) is 400 and 500 
for the global and hot-spot methods respectively.  The corresponding minimum number of 
nuclei counted is 300 and 138.  Eighteen percent of the hot-spot scores were based on <500 
nuclei counts.  Among these 126 hot-spot scores, the median number of nuclei counted is 375.  
In a context where preanalytical and staining factors are held constant, variance component 
analyses show that, regardless of scoring method, biological variation among different patients 
was the largest component of the total variation on these centrally stained slides, indicating 
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that the Ki67 score is reflecting inherent properties of the tumor (Figure 2, Supplemental Table 
5).  
Inter-observer variation of Ki67 scoring. 
Figure 3 displays the variation in scores across observers for cases in slide set 1 as spaghetti 
plots.  The corresponding plots for slide set 2-4 are displayed in Supplemental Figure 4.  Figure 4 
presents the scores in a heat map format with the columns (observers) ordered (within each 
slide set) by the median scores across cases and the rows (cases) sorted by the median scores 
across observers. 
Overall it can be seen that most observers show good parallelism in the increasing Ki67 scores 
across the plots.  In other words, observers measuring higher or lower than others tended to do 
so relatively consistently.   
Categorical concordance of Ki67 scoring. 
Regarding concordance on a categorical level (<10%, 10-20% and >20%), the relationship 
between concordance and continuous score is shown in Supplemental Figure 5.  It shows 
excellent to perfect concordance on cases with scores that are either much lower or higher than 
the intermediate range (10-20%).  
Based on visual inspection of captured images, locations of the hot-spot selections tended to 
cluster in the same region across observers within each of the excision whole section slides 
(Figure 5 shows some examples;  virtual slide images of all slides used in this study and the 
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corresponding selected fields and scores can be viewed at 
http://www.gpec.ubc.ca/papers/ki67p3b).   
The median scoring time (field selection and nuclear counting) was 9 (interquartile range: 7-11) 
and 6 (interquartile range: 4-8) minutes for global and hot-spot methods, respectively.  
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DISCUSSION 
The IKWG has demonstrated that it is possible, when controlling stringently for variability due 
to preanalytical and analytical aspects of the Ki67 immunohistochemistry assay9, and given a 
set of clearly defined training exercise and scoring instructions, for pathologists to achieve high 
inter-observer concordance in Ki67 scoring on core-cut biopsies and now on excision whole 
sections using a conventional light microscope and manual field selection, with no additional 
aid such as counting grid.   
Due to the limited sample size, we were unable to assess whether any specific method 
(weighted global, unweighted global or hot-spot) is significantly more reproducible than others.  
However, the observed ICCs for global score (weighted: 0.87; unweighted: 0.86) are relatively 
higher compared to hot-spot score (0.83) suggesting that a sufficiently powered study might be 
able to show more convincingly whether global scores are more reproducible.  This result is 
consistent with findings on core biopsies30. 
Can this level of concordance be clinically adequate?  The POETIC11 study assessed Ki67 (cut 
point at 10%) as a prognostic marker.  Applying this cut point to the data in our current study, 
17 (out of 30) cases have at most one discordance in weighted global score (Figure 4a).  There 
are cases with major discrepancies: TB036, on the same physical slide (set 2), received a 
weighted global score of 4% and of 21% from observer A and L respectively.  However, it is 
apparent (Figure 4) that cases far away from the intermediate range (10-20%) tend to have 
good agreement.  Considering that cases in our current study are a random sampling of the 
general ER+ breast cancer population, one could expect that about half of these cases would 
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fall away from the intermediate range and hence Ki67 may provide clinically adequate 
information, provided that the staining and pre-analytical factors do not add too much 
variability.  
Are the proposed scoring methods practical?  The median scoring time is 6-9 minutes 
depending on the method used.  However, an adaptive scoring protocol can be used to reduce 
scoring time if the purpose is to assess whether Ki67 is above or below a specific cut point.  For 
example, considering the global scoring method, where the maximum nuclei count is pre-
specified (i.e. 400), to determine whether a case has unweighted global score ≥ 10%, the 
pathologist can stop counting if the first field he/she scored is ≥ 40%.  For cases with very low 
Ki67 score, one would likely still need to count all 400 nuclei. 
The proposed scoring protocols do not make any recommendation concerning the required 
minimum tumor nuclei count.  This is a limitation of this study and in practice, it will be up to 
the discretion of the scoring pathologist to assess if too few tumor nuclei are available for an 
adequate Ki67 assessment.  This will depend on the percentage of positive cells scored in the 
cells available and the clinical context for the measurement.  
External quality assessment program (e.g. NordiQC34), involving comparing laboratory scores 
with reference scores in periodic assessment challenges, will likely improve inter-observer 
reproducibility further.  Recent studies suggest that an even higher level of concordance can be 
achieved with automated image analysis35-38.  The IKWG is actively conducting studies in this 
area to assess how artificial intelligence may help standardize Ki67 assessment35,38.  Also, 
20 
 
20 
 
concordance between Ki67 scores on core biopsies and excision specimens is currently being 
investigated.   
In conclusion, this study demonstrates an adequately high level of inter-observer concordance 
can be achieved by visual assessment of Ki67 using practical scoring methods, although some 
cases with large discrepancies remain.  A two-tier assessment approach may be worthy of 
further study as a means to reduce scoring burden and further address challenging cases: if the 
Ki67 value from the initial scoring falls on a grey zone (e.g., cut point +/- 5%), scoring by a 
second pathologist or alternative test could be pursued.  Preanalytical and analytical aspects of 
the immunohistochemistry assay, areas that still need standardization before the clinical utility 
of this marker can be proven, will likely add more variability.  A clinical validation study 
employing analytically reproducible methodology would also need to be completed in 
appropriate cohorts of cases to determine whether Ki67 can be recommended for patient care 
decisions.   
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TABLE 
Table 1. Summary of ICC values for different scoring methods. 
 Different-section ICC Same-section ICC 
Weighted global 0.87 (95%CI: 0.799─0.93) 0.87 (95% CI: 0.799─0.92) 
Unweighted global 0.86 (95%CI: 0.79─0.92) 0.86 (95% CI: 0.79─0.92) 
Hot-spot 0.83 (95 %CI: 0.74─0.90) 0.83 (95% CI: 0.74─0.90) 
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FIGURE LEGENDS 
Figure 1. Ki67 scores of all 23 observers (by slide set).  Observers are ordered (within each 
group) by the median scores. The bottom/top of the box in each box plot represent the first 
(Q1)/third (Q3) quartiles, the bold line inside the box represents the median and the two bars 
outside the box represent the lowest/highest datum still within 1.5 × the inter-quartile range 
(Q3-Q1). Outliers are represented with empty circles. 
Figure 2. Variance component analysis.  Variation due to different components are presented in 
a bar plot to show the relative magnitude of differences between them.  Numeric values of the 
variance components estimates and the corresponding credible intervals are shown in 
Supplemental Table 5. 
Figure 3. Variability in Ki67 scores (slide set 1 only).  Each line represents Ki67 scores from one 
observer.  Shaded region indicates Ki67 scores between 10-20%.  Scores on slide set 2-4 are 
shown in Supplemental Figure 4. 
Figure 4. Heat map of Ki67 scores (a: weighted global; b: unweighted global; c: hot-spot).  Rows 
represent cases and columns represent observers.  Green color indicates that the score is <10%, 
yellow 10-20% and red >20%.  Cases are ordered by the median scores (across observers), 
which are shown in parentheses beside the specimen number.  Observers are ordered (within 
each group) by the median scores (across cases).  The three colon-separated numbers to the 
right of the heat map represent the number of observers giving scores falling into different 
ranges: <10% (left-most), 10-20% (middle) and >20% (right-most).  For example, “15:6:1” 
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indicates that 15 observers gave a score of <10%, six observers between 10-20% and one 
observer >20%. 
Figure 5. Hot-spot field selection by different observers on the same excision whole section 
slide.  Figure 5a shows selections (indicated by red circles) on some example excision whole 
section slides.  Figure 5b is an example of a single excision whole section slide (median score: 
18%) with zoomed-in fields.  Each observer was asked to circle the area considered to be the 
hot spot (b-i).  Most observers honed in on the same general area of the slide, although 
individual selected scoring fields do not always overlap.  Figure 5b-iii and 5b-iv represent 
segments of the same area chosen by two different observers to read Ki67.  Figure 5b-v 
represents the “outlier” field selected by only one observer as the hot-spot.  
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a. Weighted global score
(median score) SLIDE SET 1 SLIDE SET 2 SLIDE SET 3 SLIDE SET 4
TB040 (0) 1 0 0 0 1 1 0 1 1 0 0 1 0 0 1 1 0 1 0 0 0 1 0 23:0:0
TB196 (3) 3 3 6 3 4 6 2 2 5 2 3 4 3 1 4 2 4 2 4 3 4 2 2 23:0:0
TB113 (6) 6 4 6 6 6 18 4 6 5 6 8 8 9 3 6 6 7 5 4 5 3 6 7 22:1:0
TB319 (6) 6 6 7 3 10 10 2 5 5 5 6 8 7 4 4 6 6 9 6 7 6 8 4 21:2:0
TB107 (6) 4 5 5 8 5 10 3 3 9 6 8 6 8 3 8 6 8 7 5 5 4 7 9 22:1:0
KMS13 (7) 7 5 8 3 8 9 2 2 8 4 11 12 9 4 10 17 11 4 8 7 3 4 6 18:5:0
TB016 (8) 6 8 8 8 10 15 5 7 8 9 11 13 21 8 13 10 10 10 6 8 7 12 7 13:9:1
KMS18 (9) 6 8 9 8 10 18 3 12 9 11 16 6 19 6 8 9 10 16 10 5 2 2 5 14:9:0
KMS3 (9) 7 9 14 9 16 12 7 7 9 7 9 8 12 9 16 12 15 12 6 11 9 11 9 13:10:0
TB022 (9) 7 8 10 5 10 15 3 10 6 13 15 5 5 8 10 7 9 7 10 6 11 11 14 12:11:0
KMS2 (10) 13 9 7 14 11 16 5 9 8 14 13 11 20 9 10 10 9 11 6 9 4 11 10 10:13:0
KMS8 (10) 11 10 12 9 18 22 9 10 10 18 15 8 22 10 11 17 10 14 8 7 9 9 10 7:14:2
KMS6 (12) 9 13 6 11 14 22 12 11 11 9 16 19 20 10 9 10 15 24 12 11 8 18 15 5:16:2
TB036 (12) 8 9 12 12 12 20 4 5 13 11 14 13 21 25 15 14 12 12 9 9 8 13 10 7:14:2
KMS11 (12) 16 10 12 13 10 23 12 14 10 11 14 10 22 7 14 19 16 7 10 12 11 11 14 2:19:2
KMS20 (14) 12 16 8 12 11 24 10 9 12 13 16 18 24 11 12 16 15 19 36 13 19 14 17 2:18:3
KMS21 (15) 11 13 16 14 16 15 11 6 11 21 30 19 24 10 15 15 20 22 11 10 15 13 17 1:18:4
TB090 (16) 14 15 17 14 15 24 20 16 11 17 15 11 16 11 21 10 22 21 14 14 20 20 22 0:18:5
KMS15 (17) 22 16 19 17 13 29 8 7 12 19 21 19 21 15 17 14 23 19 16 12 13 16 24 2:15:6
TB381 (18) 17 21 18 13 26 21 16 10 15 14 20 20 29 11 14 20 28 21 14 10 20 11 21 0:16:7
KMS14 (19) 25 27 17 19 20 24 10 12 15 15 14 28 28 16 24 15 26 20 15 24 19 18 25 0:14:9
TB083 (20) 21 18 26 23 21 32 25 10 19 19 24 19 29 15 23 17 18 20 9 16 24 28 17 1:11:11
KMS5 (25) 20 25 28 20 25 28 18 14 13 25 28 18 31 11 28 28 25 21 18 22 18 29 30 0:9:14
TB203 (26) 26 24 33 24 30 37 18 19 16 26 25 26 45 31 34 37 33 24 23 34 43 18 32 0:4:19
TB077 (30) 27 34 26 24 47 39 27 18 19 32 33 28 30 15 31 36 23 45 18 34 30 31 30 0:4:19
TB067 (32) 32 41 33 28 32 36 24 25 25 32 46 24 45 28 31 23 38 33 29 30 29 34 33 0:0:23
KMS23 (34) 35 28 35 30 47 49 24 25 32 30 38 35 46 34 39 43 45 34 30 34 34 34 40 0:0:23
TB250 (40) 40 47 46 34 39 47 42 32 37 39 44 41 51 40 50 46 50 35 27 32 40 31 40 0:0:23
KMS4 (42) 44 42 33 38 47 37 29 28 50 45 28 47 50 31 51 45 53 39 25 48 27 49 33 0:0:23
KMS19 (68) 81 75 68 67 83 64 88 60 74 70 68 62 64 61 68 81 77 82 62 58 61 62 67 0:0:23
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Sp
ec
im
en
Observer
(median score) SLIDE SET 1 SLIDE SET 2 SLIDE SET 3 SLIDE SET 4
TB040 (1) 0 2 0 1 1 1 0 1 1 1 2 0 2 0 2 1 0 1 2 1 0 2 0 23:0:0
TB196 (4) 6 3 3 4 6 5 2 2 5 5 4 2 2 4 4 2 4 2 3 4 4 5 4 23:0:0
TB319 (6) 7 6 3 8 8 10 2 4 5 9 7 5 8 4 4 6 7 8 6 6 5 8 4 22:1:0
TB113 (6) 4 6 6 7 6 9 4 7 5 8 8 6 8 4 6 6 7 5 5 4 3 6 8 23:0:0
TB107 (6) 6 5 8 6 6 11 3 3 10 6 8 8 8 2 8 6 10 7 5 5 4 7 10 19:4:0
TB016 (8) 8 5 8 10 9 15 6 7 8 13 11 8 21 7 13 10 10 9 8 6 6 12 8 14:8:1
KMS13 (8) 8 9 8 11 11 10 4 5 8 13 15 6 14 6 12 15 12 4 8 8 5 4 11 13:10:0
TB022 (10) 10 8 5 9 10 14 4 10 6 4 14 12 8 10 10 7 11 8 6 10 11 11 14 10:13:0
KMS2 (10) 9 18 13 12 7 16 5 10 8 11 13 15 21 10 10 9 10 12 10 6 5 11 11 7:15:1
KMS3 (10) 10 7 10 16 14 11 5 6 9 8 12 8 14 10 15 12 16 11 11 6 9 11 10 8:15:0
KMS6 (11) 11 10 11 14 6 21 14 9 10 19 17 10 18 11 9 10 16 21 10 12 7 17 18 4:17:2
TB036 (12) 9 8 12 12 12 19 4 5 12 13 14 10 23 29 15 14 12 12 9 9 8 13 12 7:14:2
KMS8 (12) 12 12 8 13 16 21 9 10 11 10 12 18 23 12 11 14 12 14 7 8 9 10 14 5:16:2
KMS11 (12) 14 15 14 13 19 24 12 11 12 10 13 12 27 11 12 20 13 8 12 12 10 11 15 1:20:2
KMS18 (14) 14 8 14 9 17 20 4 16 15 11 16 15 20 12 12 8 16 16 6 24 4 2 12 7:15:1
KMS21 (15) 15 10 14 15 16 14 11 6 11 18 26 19 27 12 14 15 19 21 11 13 15 13 20 1:19:3
KMS20 (15) 16 12 15 11 10 24 12 10 12 17 13 16 28 14 11 16 16 18 13 35 18 14 19 0:20:3
TB090 (18) 19 15 16 15 24 25 18 16 10 12 15 18 17 16 21 12 20 23 16 18 19 20 28 0:18:5
KMS15 (18) 13 22 18 18 21 26 8 10 19 19 25 18 22 16 16 14 22 19 15 16 16 17 26 1:15:7
TB381 (18) 21 26 15 25 18 22 19 10 17 15 23 18 32 14 13 18 30 22 12 16 20 16 22 0:14:9
KMS14 (20) 22 27 18 22 18 20 9 14 15 26 15 18 30 15 24 15 26 20 24 16 23 20 28 1:12:10
TB083 (21) 19 18 24 21 27 28 22 14 20 16 22 22 32 16 20 14 20 21 18 10 24 25 23 0:11:12
KMS5 (22) 26 20 21 25 28 28 15 14 13 16 24 22 31 11 27 28 24 18 22 20 18 29 29 0:9:14
TB077 (27) 30 26 20 44 27 31 19 22 19 28 34 24 32 18 27 36 22 28 32 24 30 28 23 0:4:19
TB203 (28) 20 29 28 30 37 36 23 20 20 24 27 24 40 27 34 33 33 25 34 24 34 22 31 0:3:20
TB067 (30) 38 30 26 32 32 28 24 22 25 25 33 30 42 26 30 24 36 30 30 31 30 34 29 0:0:23
KMS23 (34) 28 37 34 47 36 46 24 25 31 32 38 30 46 32 37 38 44 35 32 27 33 34 43 0:0:23
KMS4 (36) 31 42 37 47 35 31 32 27 50 40 33 34 44 28 48 38 56 36 49 28 24 51 36 0:0:23
TB250 (37) 25 34 36 38 44 40 42 31 36 39 36 34 48 37 50 46 45 36 30 22 38 33 37 0:0:23
KMS19 (66) 72 76 69 72 66 62 88 55 69 64 64 67 64 59 68 81 70 82 59 59 61 62 64 0:0:23
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b. Unweighted global score
Sp
ec
im
en
Observer
(median score) SLIDE SET 1 SLIDE SET 2 SLIDE SET 3 SLIDE SET 4
TB040 (1) 3 1 1 1 0 1 1 1 6 0 2 3 15 0 1 1 1 6 1 0 2 1 1 22:1:0
TB196 (6) 3 4 6 6 5 6 3 4 7 3 7 6 14 0 7 7 8 11 1 5 7 8 10 20:3:0
TB113 (8) 9 8 6 7 4 12 9 5 9 7 7 16 10 9 12 12 8 5 5 4 6 14 16 16:7:0
TB319 (9) 10 5 5 6 14 12 5 3 14 7 12 9 14 7 11 15 8 10 4 4 6 10 15 12:11:0
TB022 (10) 10 8 11 10 12 24 8 9 15 8 22 20 20 10 15 10 14 6 8 8 9 14 16 8:13:2
TB107 (12) 11 12 15 14 10 15 5 7 13 7 14 11 19 9 13 11 15 11 5 6 12 14 18 6:17:0
TB016 (14) 10 14 15 14 5 17 11 9 12 13 24 15 15 10 9 19 20 17 7 11 10 17 14 4:18:1
TB036 (14) 10 12 16 16 14 20 7 8 15 13 24 19 14 7 14 19 14 13 11 9 11 18 19 4:18:1
KMS3 (14) 11 23 20 25 26 24 8 12 5 16 29 24 14 9 20 12 20 14 4 9 9 11 22 6:10:7
KMS2 (16) 17 18 10 18 16 18 9 13 13 11 23 27 24 15 13 17 17 16 9 8 8 15 20 4:16:3
KMS13 (18) 12 15 23 19 13 25 12 18 21 18 31 26 31 18 16 6 24 21 2 14 13 17 15 2:13:8
KMS8 (18) 18 16 15 22 16 25 17 15 21 18 20 27 26 18 23 21 13 20 6 12 10 14 19 1:15:7
KMS20 (22) 19 22 20 20 22 38 17 20 20 23 35 27 29 22 22 27 25 29 21 17 22 23 28 0:7:16
KMS6 (22) 18 22 18 23 22 25 13 16 12 27 25 25 32 22 26 26 26 14 8 15 18 18 30 1:9:13
KMS5 (24) 25 24 28 29 30 27 23 15 14 23 33 35 37 28 21 24 22 34 24 17 20 23 33 0:4:19
KMS21 (24) 24 23 25 23 23 36 14 23 19 23 27 30 31 16 26 23 31 27 14 16 26 25 30 0:5:18
KMS11 (26) 22 23 28 28 28 34 14 12 29 17 35 33 39 29 21 26 25 26 15 21 30 25 33 0:4:19
KMS18 (28) 24 27 29 40 30 37 23 27 29 28 28 40 39 7 22 35 35 38 18 21 20 19 33 1:3:19
TB090 (30) 26 30 28 40 28 49 25 28 30 27 32 39 50 30 26 32 26 36 31 22 28 30 31 0:0:23
TB083 (31) 30 26 41 33 39 39 22 28 31 33 47 41 46 21 25 33 28 37 27 31 25 31 32 0:0:23
KMS15 (32) 32 32 34 31 34 37 13 26 30 27 25 39 39 30 26 32 32 27 27 18 32 37 37 0:2:21
KMS14 (34) 41 25 34 45 37 39 19 22 21 30 34 38 43 30 33 21 35 42 23 21 26 38 38 0:1:22
TB381 (35) 38 33 28 46 55 51 27 27 31 33 46 41 46 38 35 39 34 39 32 28 26 30 37 0:0:23
TB067 (43) 31 36 44 43 53 51 31 37 49 43 40 46 52 43 49 37 39 54 39 32 47 36 46 0:0:23
TB077 (45) 45 44 46 44 64 56 25 36 43 31 50 50 49 44 52 46 34 41 43 33 52 49 48 0:0:23
TB203 (47) 37 40 58 50 50 54 39 42 42 41 47 50 50 45 48 40 48 51 44 47 48 46 52 0:0:23
KMS23 (48) 52 41 46 53 58 55 42 34 42 36 52 48 55 55 52 41 51 47 46 43 43 48 57 0:0:23
TB250 (53) 48 44 57 62 57 64 32 43 48 47 51 60 54 56 54 69 53 57 40 48 49 53 49 0:0:23
KMS4 (56) 56 48 58 70 68 64 38 51 64 45 58 68 54 48 53 53 51 63 55 39 57 61 63 0:0:23
KMS19 (76) 81 83 78 97 94 76 92 68 66 65 64 79 74 71 81 82 67 84 64 66 81 56 70 0:0:23
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c. Hot-spot score
Sp
ec
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en
Observer
a
6 mm
b-i
D:5.6%
b-v
M:16.2%
b-iii
J:23.6%
b-iv
b-ii
Supplemental table 1. Cohort characteristics (from pathology reports and case notes) of the 30 cases. 
Age (years) 
 median / mean 61 / 62 
 minimum / maximum 40 / 85 
Grade 
 grade 1 (%) 5 (17%) 
 grade 2 (%) 18 (60%) 
 grade 3 (%) 7 (23%) 
Tumor size (mm) 
 median / mean 20 / 22 
 minimum / maximum 12 / 42 
Number of positive nodes 
 0 (%) 21 (70%) 
 >0 (%) 9 (30%) 
ER (IHC) 
 positive 30 (100%) 
 H-score (UK cases only) 
minimum / maximum 130 / 240 
 Percent positive (Japan cases only) 
minimum / maximum 80 / 100 
 
  
Supplemental table 2. Summary statistics for weighted global scores (0-100%)1, ordered according to observer 
median. 
Group 12 
 Observer Min. 1st Qu. Median Mean 3rd Qu. Max. SD 
B 0.9 6.6 12.4 17.8 24.1 80.8 16.4 
F 0.1 8.3 12.8 18.3 24.6 74.5 16.2 
E 0.3 7.8 12.9 18.1 26.1 67.9 14.6 
V 0.5 8.1 13 16.4 22.2 66.8 13.5 
G 0.8 9.8 14.2 20.5 25.6 82.8 17.5 
H 1 15 22.1 24.1 31 63.9 13.9 
Group 2 
 Observer Min. 1st Qu. Median Mean 3rd Qu. Max. SD 
A 0.2 3.7 9.8 14.7 19.2 87.8 17.1 
P 1.2 6.4 9.9 13.1 15.4 59.6 11.7 
R 1.2 8.6 11.1 15.9 15.9 74 15 
K 0.2 8.8 13.9 18.1 24 70.5 14.8 
T 0.4 11.8 15.4 20.3 26.8 67.5 14.3 
O 1 8.4 15.5 18.3 22.9 61.5 13.7 
L 0.4 12.9 21.8 24.4 30.1 64.5 15.9 
Group 3 
Observer  Min. 1st Qu. Median Mean 3rd Qu. Max. SD 
J 0.2 7.4 10.6 14.9 16.1 61.3 13.5 
I 1.4 10.2 14.3 19.9 27.1 68.5 15.8 
U 1 9.7 14.9 19.7 22.4 80.8 16.9 
M 0.5 9.9 15.4 21.3 25.9 76.8 17 
D 0.7 9 19.2 19.8 23.3 82.2 16.3 
Group 4 
 Observer Min. 1st Qu. Median Mean 3rd Qu. Max. SD 
Q 0.4 6.6 10.6 14.9 18.3 61.9 12.5 
W 0.3 6.7 11.3 16.5 23.1 57.5 14 
N 0.2 5.8 11.9 16.7 22.8 60.8 14.3 
X 1 9.5 13 17.8 26.4 61.8 14.1 
S 0.2 9 15.7 19 28.5 67 14.5 
Mean3 
 Min. 1st Qu. Median Mean 3rd Qu. Max. SD 
 13.1 16.4 18.1 18.3 19.9 24.4 2.8 
 
1All summary statistics are computed using the untransformed Ki67 scores. 
2Groups of observers are defined by which collection of slides they received for scoring. 
3Mean for each observer computed using untransformed Ki67 scores for 30 slides; summary statistics 
provided for that collection of observer means.  
Supplemental table 3. Summary statistics for unweighted global scores (0-100%)1, ordered according to 
observer median. 
Group 12 
 Observer Min. 1st Qu. Median Mean 3rd Qu. Max. SD 
F 0.2 9.1 13.5 17.5 21.3 71.8 13.6 
B 2 7.5 13.8 18.2 26.2 76.5 15.5 
V 0.5 8.5 14.2 17.2 21.1 68.8 13.7 
G 0.8 10 14.6 20.2 25.2 71.7 15.8 
E 0.8 9 16.6 19.5 26.9 66.5 14.2 
H 1.2 13.8 20.9 22.3 27.7 61.8 12.6 
Group 2 
Observer  Min. 1st Qu. Median Mean 3rd Qu. Max. SD 
A 0.2 4.2 10 14.8 19.2 87.8 17 
P 1.2 6.2 10.3 13.4 16 55 10.9 
R 1.2 8.6 11.6 16.4 19 69.2 14.2 
O 1 10.5 14.2 17.8 22.6 63.5 13 
T 2 12.4 15.1 19.8 26 64.5 12.9 
K 0.5 8.6 16.9 17.6 22.2 67.2 12.9 
L 1.8 15.2 22.9 25 31.7 64.5 14.8 
Group 3 
Observer  Min. 1st Qu. Median Mean 3rd Qu. Max. SD 
J 0.5 10 12.4 15.8 17.2 59.2 12.3 
I 2 10.7 13.8 19.5 26.1 68.5 15.3 
U 1 9.4 14.5 18.9 22.7 80.8 16.3 
M 0.5 11 16.4 21.3 25.1 70 15.7 
D 0.8 8.5 18 19.1 23 82.2 15.5 
Group 4 
 Observer Min. 1st Qu. Median Mean 3rd Qu. Max. SD 
W 2 7.1 11.5 16.9 23.1 59.2 13.9 
Q 0.8 6.6 12.9 15.9 23 58.8 12.1 
N 0.2 5 13.1 16.4 23.5 60.8 13.6 
X 1.5 9.9 13.4 18.1 24 61.8 14 
S 0.5 11.2 18.7 20.2 28.2 63.5 13.4 
Mean3 
 Min. 1st Qu. Median Mean 3rd Qu. Max. SD 
 13.4 16.7 18.1 18.3 19.7 25 2.6 
 
1All summary statistics are computed using the untransformed Ki67 scores. 
2Groups of observers are defined by which collection of slides they received for scoring. 
3Mean for each observer computed using untransformed Ki67 scores for 30 slides; summary statistics 
provided for that collection of observer means.  
Supplemental table 4. Summary statistics for hot-spot scores (0-100%)1, ordered according to observer 
median. 
Group 12 
 Observer Min. 1st Qu. Median Mean 3rd Qu. Max. SD 
B 2.8 11.3 22.8 25.8 36.1 81 17.9 
V 0.6 14.5 23.1 25.3 32.7 82.7 16.7 
E 1 14.8 26.3 28.1 39.2 78.4 18.7 
F 0.6 16.8 26.6 31.1 43.9 96.8 21.4 
G 0.4 13.8 26.9 30.9 47.4 94 22.6 
H 0.7 20.8 34.9 34.3 50.6 76 18.8 
Group 2 
Observer  Min. 1st Qu. Median Mean 3rd Qu. Max. SD 
A 0.6 8.8 15.6 20.1 24.8 92 17.5 
P 0.8 9.9 19.1 22 28 68.2 15.7 
R 4.6 13.5 20.7 25.7 31.2 65.6 16.5 
O 0.4 12.8 23.3 23.9 32.2 64.8 14.9 
L 2.5 23 30.2 31.4 44.5 63.6 15.4 
K 3.4 20.9 31.4 33.1 40.6 79.4 18 
T 10.4 19.6 34.3 34.4 48 73.8 16.4 
Group 3 
 Observer Min. 1st Qu. Median Mean 3rd Qu. Max. SD 
U 0.4 9.2 21.4 24.9 35.8 70.6 18.1 
M 0.8 14.4 22.5 27.5 34.7 80.6 18 
D 1.2 15.4 24.8 27.9 36.5 82.2 18.1 
J 0.8 15.5 25.4 27.5 34.5 67 15.5 
I 5 13.8 26.7 29.9 40.5 83.8 19.3 
Group 4 
 Observer Min. 1st Qu. Median Mean 3rd Qu. Max. SD 
Q 0.6 6 16.5 21.2 32.1 64.2 17.6 
N 0.4 8.8 16.9 20.9 30.1 65.6 15.6 
W 1.8 10.4 21 25.1 31.1 80.8 18.9 
X 1.4 14.3 23 26.7 36.4 60.6 15.6 
S 0.8 18 30.4 31 37.8 69.6 16.6 
Mean 3 
 Min. 1st Qu. Median Mean 3rd Qu. Max. SD 
 20.1 25 27.5 27.3 31 34.4 4.2 
 
1All summary statistics are computed using the untransformed Ki67 scores. 
2Groups of observers are defined by which collection of slides they received for scoring. 
3Mean for each observer computed using untransformed Ki67 scores for 30 slides; summary statistics 
provided for that collection of observer means.  
Supplemental table 5. Variance components estimates1 and corresponding credible intervals.  
Component Scoring method Variance estimate (95% credible interval) 
Biological 
Weighted global 1.82 (0.97 – 2.83) 
Unweighted global 1.49 (0.81 – 2.33) 
Hot-spot 1.52 (0.79 – 2.39) 
Residual 
Weighted global 0.18 (0.17 – 0.21) 
Unweighted global 0.17 (0.15 – 0.18) 
Hot-spot 0.20 (0.17 – 0.22) 
Observer 
Weighted global 0.08 (0.04 – 0.14) 
Unweighted global 0.06 (0.03 – 0.11) 
Hot-spot 0.10 (0.04 – 0.17) 
Section 
Weighted global 0.0003 (0 – 0.0014) 
Unweighted global 0.0001 (0 – 0.0004) 
Hot-spot 0.0001 (0 – 0.0002) 
 
1Variance component estimates were computed using log2-transformed Ki67 scores. 
   
   
   
   
   
   
 
